Ionis Partner Licenses Rare Kidney Disease Treatment & Will Advance Into Phase 3 Clinical Study

Ionis Pharmaceuticals, Inc. announced that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN). IgAN is a rare and serious condition that often leads to chronic kidney disease and renal failure.

Roche will lead and be responsible for the Phase 3 study of IONIS-FB-LRx in patients with IgAN and for future global development, regulatory and commercialization activities. Roche's decision to advance the program comes after positive data from a Phase 2 clinical study in which IONIS-FB . . .